medigraphic.com
ISSN 0016-3813 (Print)

2011, Number 1

<< Back Next >>

Gac Med Mex 2011; 147 (1)

Elevated stimulated thyroglobulin levels in the identification of persistent papillary thyroid carcinoma

Jervis P, González B, Vargas G, Mercado M

Language: Spanish
References: 14
Page: 12-16
PDF size: 82.81 Kb.


ABSTRACT

Background: Persistence of papillary thyroid carcinoma is usually associated with elevated stimulated thyroglobulin levels. Aim of the study: To evaluate the association between moderately elevated stimulated thyroglobulin levels and the persistence of papillary thyroid carcinoma one year after thyroidectomy and radioiodine ablation. Methods: Out of a cohort of 97 patients with papillary thyroid carcinoma, we selected those with available stimulated thyroglobulin level measurements (in the absence of thyroglobulin antibodies) after one year of initial treatment with surgery and radioiodine. The subjects were stratified according to whether the stimulated thyroglobulin level was between 1-10 ng/ml or above 10 ng/ml. Results: Twenty-seven patients were included in the study, 11 with a stimulated thyroglobulin level between 1-10 ng/ml, and 16 with values greater than 10 ng/ml. Median age and gender proportion was similar between both groups. As expected, median stimulated thyroglobulin levels were significantly greater in the second group (5.1 vs. 42 ng/ml; p ‹ 0.001). A stratified analysis aiming at associating stimulated thyroglobulin levels with disease persistence yielded an overall risk of 0.58 (95% CI: 0.1-3.09; p = 0.52) for those subjects with levels between 1-10 ng/ml, while for those with levels › 10 ng/ml the overall risk was 1.71 (95% CI: 0.32-9.1; p = 0.52). The positive predictive value for a stimulated thyroglobulin level between 1-10 ng/ml was 64%. Conclusion: A moderately elevated stimulated thyroglobulin level is an uncertain predictor of papillary thyroid carcinoma persistence.


REFERENCES

  1. Tuttle RM, Leboeuf R, Martorella AJ. Papillary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin North Am. 2007;36:753-78.

  2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164-7.

  3. Nagataki S, Nystrom E. Epidemiology and primary prevention of thyroid cancer. Thyroid. 2002;12:889-96.

  4. Sherman SI. Thyroid carcinoma. Lancet. 2003;361:501-11.

  5. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86: 1447-63.

  6. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1433-41.

  7. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab. 2003;88: 1107-11.

  8. Toubeau M, Touzery C, Arveux P, et. al. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after 131I ablation therapy in patients with differentiated thyroid cancer. J Nucl Med. 2004;45:988-94.

  9. Eustatia-Rutten CFA, Smit JWA, Romijn JA, et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol. 2004; 61:61-74.

  10. Rouxel A, Hejblum G, Bernier MO, et al. Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2004;89: 5362-8.

  11. Sherman SI, Douglas WB, David B, et al. National comprehensive cancer network, clinical practice guidelines in oncology, thyroid carcinoma V.1.2008. Disponible en http://www.nccn.org/professionals/physician_gls/PDF/thyroid.pdf.

  12. Akslen LA, LiVolsi VA. Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma. Cancer. 2000;88:1902-8.

  13. Cooper DS, Doherty GM, Haugen BR, et al. Revised american thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-214.

  14. Pacini F, E Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinology. 2006;154:787-803.




2020     |     www.medigraphic.com